Tanja Obradovic: Exciting new vaccine is about to start Phase III in advanced NSCLC patients that progressed following immunotherapy
Tanja Obradovic,
“Exciting new vaccine is about to start Phase III in advanced Non Small Cell Lung Cancer (NSCLC) patients that progressed following immunotherapy. Considering huge medical need this is great development and just announced by OSE Immunotherapeutics.
Phase III will be testing OSE2101, a T-specific immunotherapy designed to induce cytotoxic T lymphocytes (CTLs) against five tumor-associated antigens (TAAs) frequently over-expressed in NSCLC (HER-2/neu, CEA, MAGE 2, MAGE 3 and p53).
OSE2101 is a vaccine composed of nine synthetic peptides from these TAAs that are presented in lung cancer cells by the human leukocyte antigen (HLA)-A2 phenotype, which occurs in up to 45% of the population. After very promising results including potential to deliver OS benefit in ATLANTE-1 trial in 3 more line.
New Phase III protocol designed for 2 more line in HLA-A2 positive patients is under review of FDA with planned start this year. Non Small Cell Lung Cancer (NSCLC) PD(L)-1 Phase III immunooncology strategy late stage oncology clinical development FDA cancer therapy checkpoint inhibitor relapse HLA-A2.”
Additional information.
Source: Tanja Obradovic/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023